Alkermes (ALKS) Stock Forecast & Price Target

Compare

572 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

8 Buy

5 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$43.33

▲(28.16% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $43.33 with a high forecast of $50.00 and a low forecast of $34.00. The average price target represents a 28.16% change from the last price of $33.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","38":"$38","51":"$51","31.5":"$31.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,31.5,38,44.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,32.184615384615384,33.669230769230765,35.15384615384615,36.63846153846154,38.12307692307692,39.607692307692304,41.09230769230769,42.57692307692308,44.06153846153846,45.54615384615384,47.03076923076923,48.51538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,31.67153846153846,32.64307692307692,33.614615384615384,34.58615384615385,35.55769230769231,36.529230769230765,37.50076923076923,38.472307692307695,39.44384615384615,40.41538461538461,41.386923076923075,42.35846153846154,{"y":43.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,30.953846153846154,31.20769230769231,31.46153846153846,31.715384615384615,31.96923076923077,32.223076923076924,32.47692307692308,32.73076923076923,32.98461538461538,33.238461538461536,33.49230769230769,33.746153846153845,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$43.33

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joon Lee

Truist Financial

$50

Buy

47.89%

Upside

Initiated

11/11/25

Alkermes (ALKS) Receives a New Rating from a Top Analyst

Leonid Timashev

RBC Capital

$47

Buy

39.01%

Upside

Reiterated

11/10/25

Alkermes (ALKS) Gets a Buy from RBC Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

47.89%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Douglas Tsao

H.C. Wainwright

$32.89→$46

Hold

36.05%

Upside

Reiterated

11/09/25

Alkermes (ALKS) Receives a Hold from H.C. Wainwright

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

24.22%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)We rate ALKS shares Buy.

Ami Fadia

Needham

$43→$44

Buy

30.14%

Upside

Assigned

10/29/25

Alkermes: Strong Financial Performance and Positive Outlook Justify Buy RatingWe anticipate a positive move in the stock today based on the strong revenue beat and raised 2025 guidance.

Uy Ear

Mizuho Securities

$40→$45

Hold

33.10%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securitiesraising our PT from $40 to $45 and reiterating our OP.

Benjamin Burnett

Wells Fargo

$44→$42

Buy

24.22%

Upside

Reiterated

10/29/25

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), Medtronic (NYSE: MDT) and UnitedHealth (NYSE: UNH)3Q25 Update: We Have Conviction in (At A Minimum) Pos. Trends Emerging

Joseph Thome

TD Cowen

$38→$40

Buy

18.31%

Upside

Reiterated

10/28/25

Alkermes' Strong Financial Performance and Strategic Moves Justify Buy RatingWe feel encouraged by the continued solid performance from ALKS' three marketed products, which continues to serve as a steady base business for the company while its orexin 2 receptor agonist pipeline matures. We note the OX2R agonist platform remains the main focus for investors, with all eyes currently on the topline data release from the Ph. II study of alixorexton in NT2 patients expected next month.

Jason Gerberry

Bank of America Securities

$33→$34

Hold

0.56%

Upside

Reiterated

10/28/25

Alkermes price target raised to $34 from $33 at BofAAlkermes price target raised to $34 from $33 at BofA

David Amsellem

Piper Sandler

$38→$45

Buy

33.10%

Upside

Reiterated

10/23/25

Alkermes (ALKS) Gets a Buy from Piper SandlerRaising PT to $45 from $38; We reiterate our Overweight rating

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Jessica Fye

J.P. Morgan

$34→$35

Hold

3.52%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Akash Tewari

Jefferies

$50→$54

Buy

59.72%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-22.72%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joon Lee

Truist Financial

$50

Buy

47.89%

Upside

Initiated

11/11/25

Alkermes (ALKS) Receives a New Rating from a Top Analyst

Leonid Timashev

RBC Capital

$47

Buy

39.01%

Upside

Reiterated

11/10/25

Alkermes (ALKS) Gets a Buy from RBC Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

47.89%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Douglas Tsao

H.C. Wainwright

$32.89→$46

Hold

36.05%

Upside

Reiterated

11/09/25

Alkermes (ALKS) Receives a Hold from H.C. Wainwright

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

24.22%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)We rate ALKS shares Buy.

Ami Fadia

Needham

$43→$44

Buy

30.14%

Upside

Assigned

10/29/25

Alkermes: Strong Financial Performance and Positive Outlook Justify Buy RatingWe anticipate a positive move in the stock today based on the strong revenue beat and raised 2025 guidance.

Uy Ear

Mizuho Securities

$40→$45

Hold

33.10%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securitiesraising our PT from $40 to $45 and reiterating our OP.

Benjamin Burnett

Wells Fargo

$44→$42

Buy

24.22%

Upside

Reiterated

10/29/25

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), Medtronic (NYSE: MDT) and UnitedHealth (NYSE: UNH)3Q25 Update: We Have Conviction in (At A Minimum) Pos. Trends Emerging

Joseph Thome

TD Cowen

$38→$40

Buy

18.31%

Upside

Reiterated

10/28/25

Jason Gerberry

Bank of America Securities

$33→$34

Hold

0.56%

Upside

Reiterated

10/28/25

Alkermes price target raised to $34 from $33 at BofAAlkermes price target raised to $34 from $33 at BofA

David Amsellem

Piper Sandler

$38→$45

Buy

33.10%

Upside

Reiterated

10/23/25

Alkermes (ALKS) Gets a Buy from Piper SandlerRaising PT to $45 from $38; We reiterate our Overweight rating

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Jessica Fye

J.P. Morgan

$34→$35

Hold

3.52%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Akash Tewari

Jefferies

$50→$54

Buy

59.72%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-22.72%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

+4.32%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +4.32% per trade.

3 Months

xxx

Success Rate

14/18 ratings generated profit

Average Return

+7.08%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.08% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

16/18 ratings generated profit

Average Return

+20.74%

reiterated a buy rating 8 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +20.74% per trade.

2 Years

xxx

Success Rate

20/22 ratings generated profit

Average Return

+14.07%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +14.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 28 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 43.33.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.42 with a range of $0.29 to $0.50. The previous quarter’s EPS was $0.68. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $377.40M with a range of $356.85M to $400.80M. The previous quarter’s sales results were $394.19M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 43.33.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 28.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 43.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $34.00. The average price target represents 28.16% Increase from the current price of $33.81.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts